2000 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
No.23
“Distinctly altered gut microbiota in the progression of liver disease” (Oncotarget, 7: 19355-19366, 2016)
VIEW ARTICLE 
No.22
“Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes“ (Diabetology & Metabolic Syndrome, 8:45, 2016)
VIEW ARTICLE
No.21
“Solithromycin Diminishes Steatohepatitis by Modulating Gluconeogenesis and Inhibits Tumor Growth in a Diabetic Mouse Model of Non-Alcoholic Steatohepatitis” (J Immunol Infect Inflam Dis, 1:004, 2016)
VIEW ARTICLE
No.20
“Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis“ (PLoS One, 11:e0158156, 2016)
VIEW ARTICLE
No.19
“Cancer-Associated Fibroblasts Regulate Tumor-Initiating Cell Plasticity in Hepatocellular Carcinoma through c-Met/FRA1/HEY1 Signaling” (Cell Press, 15:1175-1189, 2016)
VIEW ARTICLE
No.18
“Palmitate-induced Regulation of PPARγ via PGC1α: a Mechanism for Lipid Accumulation in the Liver in Nonalcoholic Fatty Liver Disease” (Int. J. Med. Sci, 13:169-178, 2016)
VIEW ARTICLE
No.17
“Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model” (Eur J Pharmacol, 772:22-32, 2016)
VIEW ARTICLE